Kimer Med: High Impact NZ Biotech company

Kimer Med is a New Zealand biotech company with global potential. We're developing a family of new, broad-spectrum antiviral therapeutics to treat a range of viral diseases and to provide protection against the next pandemic.

About us:

Kimer Med is led by vastly experienced Director and entrepreneur, Rick Kiessig (co-founder, CEO, CSO), and Lead Scientist Dr Sophie Walker, a specialist in protein engineering, analytical biochemistry and biophysics.

Our R&D is undertaken in our fully equipped PC-2 laboratory in Nelson, New Zealand, leveraging the region’s internationally-renowned scientific community as well as our global networks and partners.

Kimer Med was founded to save lives and reduce the suffering caused by viral diseases, by developing and commercialising broad-spectrum antiviral technology. Our approach supports both treatment (after infection), and short-term prevention (before infection). Our small, agile team is motivated, passionate and determined to build a successful business that will change the world.

Opportunity to purchase Ordinary Shares

Philip Oliver, a co-founder of Kimer Med and Director of our Company has moved away from the day-to-day role he has had. This will free Philip up to pursue other opportunities he has put on hold. His valuable work for the Company has been much appreciated and he has transitioned his role to other team members on the ground in Nelson. He will remain a valued member of Kimer Med’s Board. Philip is offering up to 20% of the shares he owns for sale at NZD $1.80/each. These shares are Ordinary Shares, which is the same class of shares as owned by the other founders of Kimer Med.

Philip Oliver says: "I am a co-founder of Kimer Med. I'm 62 years old and no longer actively involved in the company day to day, and pursuing other opportunities. I own close to 5 million shares of the company and would like to raise some money in the near term by selling up to 1 million of those shares."

Please read Kimer Med’s most recent Information Memorandum (IM) and July 2025 information update available to download from the 'Key documents' tab on this page.

The Opportunity

The Global Antiviral Market:

The global antiviral market is poised for continued growth, driven by innovation, the increasing prevalence and severity of viral diseases, and pandemic preparedness efforts. As the global community continues to confront viral threats, access to safe and effective antiviral therapies remains paramount to protect public health and improve patient outcomes.

The market is currently worth NZ$97 billion dollars in annual sales revenue, with a compound annual growth rate (CAGR) of approximately 5.5%.

This figure represents the value of antivirals for only 12 viruses.

Kimer Med’s goal is to expand the existing market by producing and commercialising a family of new broad-spectrum antivirals against multiple diseases for which there are currently no approved treatments available. Our first target is the Dengue virus - a $3.8b opportunity.

Investment Highlights:

• Success against 19 viruses in vitro (lab-based testing) to date
• First in vivo (in animals) study confirmed antivirals' safety and efficacy (further studies in mice are underway)
• Proprietary VTose Antiviral Platform technology enables rapid antiviral development and optimisation, reducing discovery time
• US DOD-funded contract underway for custom antiviral development worth up to NZ$1.3 million (non-dilutive)
• Lead antiviral compound shows up to 100% efficacy in vitro against all four types of Dengue, and Zika virus
• Annual Dengue cases number more than 400 million, with no antiviral available - an opportunity worth NZ$3.8 billion annually
• A detailed project plan and business growth strategy based on out-licencing after phase 1 trials, with profitability forecast by 2028

Please also see business updates available under the Key documents tab above.